IFNG and infection: Six weeks after challenge, the bacterial burden in the lungs was significantly reduced in the BCG-injected group compared to the infection control group, but the bacterial burden was not reduced in the Rv2005c-immunized group (Figure S4B), although Rv2005c-specific IFN-γ production was observed in lung cells in the Rv2005c-immunized group (Figure S4C).